ReviewInternational journal of clinical and experimental medicine2015
Autotaxin-LPA receptor axis in the pathogenesis of lung diseases.
Review in International journal of clinical and experimental medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 19 citations in OpenAlex.
- Safety, Pharmacokinetics, and Pharmacodynamics of the Autotaxin Inhibitor GLPG1690 in Healthy Subjects: Phase 1 Randomized Trials.Journal of clinical pharmacology · 2019Trial
- The Autotaxin-LPA Axis Emerges as a Novel Regulator of Smooth Muscle Cell Phenotypic Modulation during Intimal Hyperplasia.International journal of molecular sciences · 2023Article
- Lysophosphatidic acid species are associated with exacerbation in chronic obstructive pulmonary disease.BMC pulmonary medicine · 2021Article
- A Novel Therapeutic Reagent, KA-1002 for Alleviating Lysophosphatidic Acid-Mediated Inflammation Related Gene Expression in Swine Macrophages.Animals : an open access journal from MDPI · 2020Article
- Autotaxin-Lysophosphatidic Acid Axis Blockade Improves Inflammation by Regulating Th17 Cell Differentiation in DSS-Induced Chronic Colitis Mice.Inflammation · 2019Article
- Lysophosphatidic Acid Signaling in Diabetic Nephropathy.International journal of molecular sciences · 2019Review
- Review
- Characterization of the properties of a selective, orally bioavailable autotaxin inhibitor in preclinical models of advanced stages of liver fibrosis.British journal of pharmacology · 2018Article
- Metabolomics analysis reveals that benzo[a]pyrene, a component of PMRedox biology · 2017Article
- Metabolomics analysis identifies sex-associated metabotypes of oxidative stress and the autotaxin-lysoPA axis in COPD.The European respiratory journal · 2017Article
- Adult Lysophosphatidic Acid Receptor 1-Deficient Rats with Hyperoxia-Induced Neonatal Chronic Lung Disease Are Protected against Lipopolysaccharide-Induced Acute Lung Injury.Frontiers in physiology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lysophosphatidic acid (LPA) is a small lipid which mediates a variety of cellular functions via the activation of LPA receptors. LPA is generated from lysophosphatidylcholine by the extracellular enzyme, autotaxin (ATX). Elevated ATX expression, LPA production and their signaling pathways have been reported in multiple pathological conditions of lung tissue, including inflammation, fibrosis and cancer. Emerging evidence has highlighted the importance of ATX and LPA receptors in the pathogenesis of lung diseases. Here, we briefly review the current knowledge of different roles of the ATX-LPA receptor axis in lung diseases focusing on inflammation, fibrosis and cancer.
Indexed as
Identifiers
26770305PMC4694205W2398850357What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.